Advertise on podcast: The BioHub: The Top Voices in Biotech

Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent. Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the course of her career, she’s built and scaled people strategies across both life sciences and financial services, holding senior HR leadership roles at organizations like the Broad Institute of MIT and Harvard, Warp Drive Bio, Aegerion Pharmaceuticals, and several major financial institutions. In this we discuss: Kim's 8.5 year journey so far at Fulcrum, from a small, ambitious biotech to the more mature, resilient organization it is today.Restructuring and the lessons learnt about leadership,communication, and empathy during times of crisisKim's new book 'The Culture Shock'

In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics. Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies. We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and why their precision gene therapy approach is so exciting. It’s a thoughtful conversation about mindset, leadership, and what it really takes to build in small biotech.

We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio. Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. In this we cover: The spark that led to the founding of Enara BioEnara's platform EDAPT® and how it finds dark antigens in tumors.Where the field of T-Cell therapy for solid tumors is today.The importance of culture in early stage biotech, and how the company has been built around putting people first.The next major milestones for Enara Bio.

JPM Special — Maureen Hillenmeyer, CEO & Founder of Hexagon Bio In this JPM Special episode of The BioHub, I’m joined by Maureen Hillenmeyer, CEO and Founder of Hexagon Bio. Maureen has built Hexagon around a bold idea: using genomics, computation, and the biology of natural products to unlock entirely new medicines. At JPM, we sat down to talk about what it really takes to build a platform company in today’s market — from scientific conviction and capital discipline to leadership, culture, and long-term vision. We also discuss: What makes Hexagon’s approach fundamentally different How Maureen thinks about risk, focus, and scale as a founder-CEO The realities of building biotech through multiple market cycles A thoughtful, grounded conversation with one of the most impressive founders in the space.

I’m here with Mike Exton, the CEO of LexiconPharmaceuticals. Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto. Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built around delivering best-in-class or first-in-class medicines in areas of real unmet need. Mike, great to have you here

In our first JPM Special 2026, we’re joined by Dirk Thye, CEO of Quince Therapeutics, as the company approaches a defining Phase 3 readout. A candid conversation about high-stakes data, leadership under pressure, and what a true do-or-die moment looks like in biotech.

Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precision medicine, helping advance novel therapeutic programs and navigating the complex path from early discovery to clinical development. At Delphia Therapeutics, Kevin is leading the development of a new approach to precision oncology known as activation lethality—an emerging strategy designed to uncover previously untapped cancer vulnerabilities and deliver more targeted, effective treatments. With a background that blends rigorous science, entrepreneurial leadership, and a patient-first mindset, Kevin brings a thoughtful perspective on the future of cancer therapy, innovation in biotech, and what it truly takes to build a science-driven company from the ground up. We’re excited to have him with us today.

On this episode we're joined by Invivo Partners' Gemma Guinart, for a discussion into early-stage biotech investing. Invivo Partners look to invest in compelling in-vivo proof of concept data, and back founding teams across Europe with pre-seed to Series A investment - recent investments from their third fund include Neumirna Tx & Signadori Bio. Tune in to hear more about how Gemma & the team identify investment opportunities & why they focus on early-stage investments in a market that has recently leaned toward late-stage de-risked assets. We also chat briefly through some potential pitfalls for founders looking for funding, their newest fund bridging healthcare & AI, and success stories from the Invivo Partners portfolio, including EsoBiotec.

We're joined by Ahmet Tutuncu, CEO of AeroRx Therapeutics, to discuss their novel, best-in-class nebulized combination product for moderate-to-severe COPD patients. AeroRx's pipeline includes AERO-007, the first nebulized LABA/LAMA combination in clinical development, and AERO-111, the first triple LABA/LAMA/ICS nebulized therapy in IND-enabling studies. Ahmet previously co-founded Elevation Pharma and Patara Pharma, both acquired for their inhaled-drug platforms. In a wide ranging discussion we also discuss the deal-making streak in the COPD space, starting with Merck's acquisition of Verona Pharma in mid-2025, and highlighted by the recent launch of AirNexis.

On this episode we feature the CEO of Resolution Therapeutics, Amir Hefni. Throughout his career, Amir has held roles with global powerhouses such as BMS, Ipsen, & Novartis, before transitioning to small biotech with Resolution in 2023. Resolution's pipeline of regenerative macrophage therapies originates from research out of Edinburgh University. With potential across inflammatory & fibrotic diseases, the team are currently focused on patients with end-stage liver cirrhosis who otherwise only have transplantation as a treatment option. Tune in to hear more about Resolution's ongoing ph1/2 trials & what to look out for from them in 2026. We also discussed Amir's findings during the transition from big pharma to small biotech, plus the pro's & con's of building in biotech in The UK.

Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases. With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin brings a unique blend of scientific rigor, operational leadership, and business insight. He’s worked across the full lifecycle of drug development—from early strategy to commercialization—always with a focus on making a real impact for patients with unmet medical needs. Justin is also a Harvard-trained chemist, graduating magna cum laude with highest honors, and he’s passionate about translating complex science into therapies that can truly change lives.

We recently sat down with Miquel Vila-Perello, CEO of SpliceBio, at Jefferies - during which the team picked up the Series B Raise of the Year at the 2025 ELAs for their $135million round earlier this year. SpliceBio are a Barcelona-based gene therapy company using a proprietary Protein Splicing platform to address diseases caused by large genes that traditional AAV vectors can’t deliver. Their lead program, SB-007 for Stargardt disease, is currently being investigated in their Phase 1/2 ASTRA study, marking a key clinical milestone in a condition with no approved treatments. It was great to sit down with Miquel and hear about his journey in biotech & the origins of SpliceBio. He also shared some advice for other scientific co-founders stepping into the CEO-hotseat & his take on why Barcelona is well positioned to be the next EU biotech hot-spot.

We were delighted to be joined by Jason Cole, a seasonedbiotechnology executive and the CEO of Zag Bio, a Cambridge-based biotech company taking a novel approach to autoimmune disease, onto The BioHub! Jason brings more than two decades of leadership experience across the biotech industry, spanning company formation, drug development, corporate strategy, and commercialization. Before joining Zag Bio, he heldsenior executive roles at several innovative life-science companies, including bluebird bio, where he served in multiple leadership positions across strategy, operations, finance, and legal affairs. He has also led and advised emerging biotech companies as both a CEO and board member. At Zag Bio, Jason is leading a bold effort to rethinkhow autoimmune diseases are treated. Their work aims to address the root cause of autoimmunity, with the potential for more durable and transformative therapies. We’re excited to talk with Jason today about his careerjourney, the science behind Zag Bio, and what it takes to build the next generation of biotech innovation.

Today on The BioHub, I’m joined by Brendan Teehan, Chief Commercial Officer at Pacira BioSciences. Brendan has spent three decades building and leading commercial teams across biopharma, from Johnson & Johnson to Amgen, Tesaro, and Acadia. Now at Pacira, he’s driving the company’s mission to transform pain management through innovative non-opioid therapies. In this conversation, we get into what inspired him to join Pacira, how the company has evolved, and how they’ve aligned the entire organization around a clear and bold mission. We also dive into leadership, culture, and the future of pain management. Let’s get into it.

We recently spoke to Lance Baldo, CEO of Beacon Therapeutics, during the Jefferies Healthcare Conference.  Beacon's Vista ph3 trial for laru-zova, their AAV Gene Therapy for X-Linked Retinitis Pigmentosa, has completed enrolment with topline expected in mid-2026. Listen in to hear about Lance's career, from roles with Roche in both Switzerland & New Zealand to a return to the US with Genentech's ophthalmology division, and how he's drawn on those experiences in his role as CEO of Beacon. We also cover Lance's experience as a first-time CEO, and his advice for other executives making that transition, on topics as broad as fundraising, regulatory discussions, and team building.  And of course, we cover the story behind Beacon & their mission to deliver a step-change for XLRP patients globally.